Cookies?
Library Header Image
LSE Research Online LSE Library Services

Personalizing health care: feasibility and future implications

Godman, Brian B., Finlayson, Alexander E., Cheema, Parneet K, Zebedin-Brandl, Eva, Gutiérrez-Ibarluzea, Iñaki, Jones, Janelle M., Malmström, Rickard E., Asola, Elina, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Bucsics, Anna, Campbell, Stephen, Diogene, Eduardo, Ferrario, Alessandra, Fürst, Jurij, Garuoliene, Kristina, Gomes, Miguel, Harris, Katharine, Haycox, Alan, Herholz, Harald, Hviding, Krystyna, Jan, Saira, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Lööv, Sven-Ake, Malinowska, Kamila, Martin, Andrew, McCullagh, Laura, Nilsson, Fredrik, Paterson, Ken, Schwabe, Ulrich, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Tomek, Dominik, Vlahovic-Palcevski, Vera, Voncina, Luka, Wladysiuk, Magdalena, van Woerkom, Menno, Wong-Rieger, Durhane, Zara, Corrine, Ali, Raghib and Gustafsson, Lars L (2013) Personalizing health care: feasibility and future implications. BMC Medicine, 11 (1). p. 179. ISSN 1741-7015

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (767kB) | Preview
Identification Number: 10.1186/1741-7015-11-179

Abstract

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

Item Type: Article
Official URL: http://www.biomedcentral.com/
Additional Information: © 2013 The Authors
Divisions: Social Policy
LSE Health
Subjects: R Medicine > RA Public aspects of medicine
Sets: Departments > Social Policy
Research centres and groups > LSE Health
Date Deposited: 02 Apr 2014 14:52
Last Modified: 20 Jun 2019 01:50
Projects: VR 2011–3440, VR 2011–7381
Funders: Karolinska Institutet, Sweden, Swedish Research Council
URI: http://eprints.lse.ac.uk/id/eprint/56378

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics